A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Cancer Research

• Publication date

  2009-05-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-08-0938PMID 19417029PMCID PMC7213754
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer.

  2009cited by this paper
• MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer

  2008cited by this paper
• Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma

  2007cited by this paper
• ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia

  2007cited by this paper
• Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor

  2007cited by this paper
• Targeted therapy for cancer stem cells: the patched pathway and ABC transporters

  2007cited by this paper
• ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance.

  2007cited by this paper
• Multidrug Resistance and Stem Cells in Acute Myeloid Leukemia

  2006cited by this paper
• In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2).

  2006cited by this paper
• Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.

  2006cited by this paper
• Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.

  2005cited by this paper
• Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours

  2005cited by this paper
• Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.

  2005cited by this paper
• Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

  2005cited by this paper
• Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis

  2005cited by this paper
• A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced Malignancy

  2004cited by this paper
• A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.

  2004cited by this paper
• Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576.

  2003cited by this paper
• Microtubule-Targeting Natural Products

  2003cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma

  2002cited by this paper
• In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

  2001cited by this paper
• Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration.

  2000cited by this paper
• Efflux of Rhodamine From CD56+ Cells as a Surrogate Marker for Reversal of P-Glycoprotein–Mediated Drug Efflux by PSC 833

  1999cited by this paper
• Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833.

  1999cited by this paper
• The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein

  1999cited by this paper
• Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.

  1998cited by this paper
• Clinical trials of P-glycoprotein reversal in solid tumours.

  1996cited by this paper
• Pharmacological considerations in the modulation of multidrug resistance.

  1996cited by this paper
• Clinical studies with modulators of multidrug resistance.

  1995cited by this paper
• Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi.

  1994cited by this paper
• Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.

  1993cited by this paper
• Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes.

  1992cited by this paper
• Bio-analysis of vinorelbine by high-performance liquid chromatography with fluorescence detection.

  1992cited by this paper
• Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines.

  1985cited by this paper
• Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts.

  1979cited by this paper
• A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

  1976cited by this paper

• Research Progress on the Mechanisms of Action, Pharmacological Activities and Clinical Application of P-glycoprotein Inhibitors.

  2026cites this paper
• Enhancing ferroptosis and inhibiting ABCB1 make the novel aldose reductase inhibitor 5F-E a promising sensitizer in liver cancer

  2025cites this paper
• Enhanced plasma and brain concentrations and medulloblastoma cytotoxicity of asciminib and nilotinib by P-glycoprotein inhibition with tariquidar.

  2025cites this paper
• Revisiting strategies to target ABC transporter-mediated drug resistance in CNS cancer

  2025influential citation
• Repurposing the Tyrosine Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Cancer Therapy: A Comprehensive Review

  2025cites this paper
• Effect of Different Doses of Dexamethasone on the Penetration of Acyclovir Across the Blood-Brain Barrier.

  2025cites this paper
• Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition

  2025cites this paper
• Performance and Sensitivity of [99mTc]Tc-sestamibi Compared with Positron Emission Tomography Radiotracers to Measure P-glycoprotein Function in the Kidneys and Liver

  2024cites this paper
• Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of ABCB1 in Non-small Cell Lung Cancer

  2024cites this paper
• The association of ABC proteins with multidrug resistance in cancer.

  2024cites this paper
• Inhibition of P-Glycoprotein Asymmetrically Alters the In Vivo Exposure Profile of SGC003F: A Novel Guanylate Cyclase Stimulator

  2024cites this paper
• BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo

  2024cites this paper
• Comparative in vivo biodistribution and pharmacokinetic evaluation of phenytoin sodium loaded polymeric nanomicelles and marketed phenytoin sodium iv

  2024cites this paper
• ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery

  2023cites this paper
• Insights into the involvement of long non-coding RNAs in doxorubicin resistance of cancer

  2023cites this paper
• Pharmaceutical polymers and P-glycoprotein: Current Trends and Possible Outcomes in Drug Delivery

  2023cites this paper
• Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines

  2022cites this paper
• USP7 Induces Chemoresistance in Triple-Negative Breast Cancer via Deubiquitination and Stabilization of ABCB1

  2022cites this paper
• Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells

  2022cites this paper
• Novel Sigma-2 receptor ligand A011 overcomes MDR in adriamycin-resistant human breast cancer cells by modulating ABCB1 and ABCG2 transporter function

  2022cites this paper
• Discovery of a Flavonoid FM04 as a Potent Inhibitor to Reverse P-Glycoprotein-Mediated Drug Resistance in Xenografts and Improve Oral Bioavailability of Paclitaxel

  2022cites this paper
• Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer

  2022cites this paper
• Phytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways.

  2021cites this paper
• Tumor-targeting pH/redox dual-responsive nanosystem epigenetically reverses cancer drug resistance by co-delivering doxorubicin and GCN5 siRNA.

  2021cites this paper
• Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low‐grade glioma

  2021cites this paper
• Role of ABCB1 in Mediating Chemo-resistance of Triple Negative Breast Cancers.

  2021cites this paper
• Dietary Bioactive Diindolylmethane Enhances the Therapeutic Efficacy of Centchroman in Breast Cancer Cells by Regulating ABCB1/P-gp Efflux Transporter.

  2021cites this paper
• Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue

  2021cites this paper
• Multidrug Resistance in Mammals and Fungi—From MDR to PDR: A Rocky Road from Atomic Structures to Transport Mechanisms

  2021cites this paper
• The Long-Term DEHP Exposure Confers Multidrug Resistance of Triple-Negative Breast Cancer Cells through ABC Transporters and Intracellular ROS

  2021cites this paper
• BMI1 activates P-glycoprotein via transcription repression of miR-3682-3p and enhances chemoresistance of bladder cancer cell

  2021cites this paper
• The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP

  2020cites this paper
• Role of ATP-Binding Cassette Transporter Proteins in CNS tumors: Resistance-based perspectives and clinical updates.

  2020cites this paper
• Role of endoplasmic reticulum stress in size-dependent inhibition of P-glycoprotein by silver nanoparticles in multidrug-resistant breast cancer cells

  2020cites this paper
• Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics

  2020cites this paper
• Reversal of ABCB1-related multidrug resistance by ERK5-IN-1

  2020cites this paper
• ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma.

  2019cites this paper
• A Machine Learning-Based Prediction Platform for P-Glycoprotein Modulators and Its Validation by Molecular Docking

  2019cites this paper
• Prolonged inhibition of P-glycoprotein after exposure to chemotherapeutics increases cell mortality in multidrug resistant cultured cancer cells

  2019cites this paper
• The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines

  2019cites this paper
• Reversal of P-Glycoprotein and Breast Cancer Resistance Protein Mediated Multidrug Resistance In Vitro Using In Silico Identified Novel Compounds

  2019cites this paper
• Multidrug Resistance Protein 1 Deficiency Promotes Doxorubicin-Induced Ovarian Toxicity in Female Mice

  2018cites this paper
• How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?

  2018cites this paper
• Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration

  2018cites this paper
• Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy

  2018cites this paper
• Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.

  2017cites this paper
• Role of P‐glycoprotein inhibitors in ceramide‐based therapeutics for treatment of cancer

  2017cites this paper
• Cepharanthine hydrochloride reverses P‑glycoprotein-mediated multidrug resistance in human ovarian carcinoma A2780/Taxol cells by inhibiting the PI3K/Akt signaling pathway.

  2017cites this paper
• Influence of the dual combination of silymarin and (-)-epigallocatechin gallate, natural dietary flavonoids, on the pharmacokinetics of oxcarbazepine in rats.

  2017cites this paper
• Effect of P-glycoprotein Mediated Inhibition in Drug Bioavailability

  2017cites this paper
• Small Molecules for Active Targeting in Cancer

  2016cites this paper
• Pharmacokinetics, biodistribution and intratumoral distribution of Celludo nanoparticles

  2016cites this paper
• Understanding the role of tariquidar, a potent Pgp inhibitor, in combination trials with cytotoxic drugs: What is missing?

  2016cites this paper
• Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform

  2016cites this paper
• Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?

  2016cites this paper
• Antimicrobial Drug Efflux Pump Inhibitors

  2016cites this paper
• P-gp Inhibitors: A Potential Tool to Overcome Drug Resistance in Cancer Chemotherapy

  2016cites this paper
• Combination liposome-based anti-cancer preparations

  2016cites this paper
• Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats

  2016cites this paper
• Molecular Effects of the Nampt Inhibitor FK866 on Leukemia Cells

  2016cites this paper
• Nanoparticle delivery systems for siRNA-based therapeutics.

  2016cites this paper
• Mutual regulation and targeting of multidrug resistance and cancer stem phenotype

  2016cites this paper
• Delivery of therapeutics using nanocarriers for targeting cancer cells and cancer stem cells.

  2015cites this paper
• Changed expression and function of P-gp in peripheral blood CD56 + cells predicting chemoresistance in non-Hodgkin lymphoma patients

  2015cites this paper
• Nanobiotechnological Approaches to Overcome Drug Resistance in Breast Cancer.

  2015cites this paper
• Increased Permeability-Glycoprotein Inhibition at the Human Blood–Brain Barrier Can Be Safely Achieved by Performing PET During Peak Plasma Concentrations of Tariquidar

  2015cites this paper
• Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors

  2015cites this paper
• In vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatin

  2015cites this paper
• Inhibition of P-glycoprotein Gene Expression and Function Enhances Triptolide-induced Hepatotoxicity in Mice

  2015cites this paper
• APO866 Increases Antitumor Activity of Cyclosporin-A by Inducing Mitochondrial and Endoplasmic Reticulum Stress in Leukemia Cells

  2015cites this paper
• Multidrug resistance-associated protein 2 (MRP2) and oxaliplatin transport

  2015cites this paper
• Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer.

  2014cites this paper
• Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?

  2014cites this paper
• The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy

  2014cites this paper
• The pharmacological point of view of resistance to therapy in tumors.

  2014cites this paper
• Nanomedicine to overcome cancer multidrug resistance.

  2014cites this paper
• P-Glycoprotein Phosphorylation and Transport Activity in Rainbow Trout (Oncorhynchus mykiss) Hepatocytes.

  2014cites this paper
• ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition

  2014cites this paper
• Increased P-gp inhibition at the human blood brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar

  2014cites this paper
• 99mTc Sestamibi as a Prognostic Factor of Response to First-Line Therapy and Outcome in Patients With Malignant Lymphoma

  2013cites this paper
• Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line.

  2013cites this paper
• Reversal of MRP7 (ABCC10)-Mediated Multidrug Resistance by Tariquidar

  2013cites this paper
• ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein

  2013cites this paper
• P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives.

  2013cites this paper
• Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles.

  2013cites this paper
• Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.

  2012cites this paper
• HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1.

  2012cites this paper
• Drug Efflux Transporters and Multidrug Resistance in Acute Leukemia: Therapeutic Impact and Novel Approaches to Mediation

  2012cites this paper
• Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies?

  2012cites this paper
• Cancer resistance to type II topoisomerase inhibitors.

  2012cites this paper
• Effect of magnetic nanoparticles of Fe3O4 and wogonin on the reversal of multidrug resistance in K562/A02 cell line

  2012cites this paper
• Increased expression and function of P-glycoprotein in peripheral blood CD56+ cells is associated with the chemoresistance of non-small-cell lung cancer

  2012cites this paper
• ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of IPH-926 human lobular breast cancer cells.

  2012cites this paper
• Investigational ABC transporter inhibitors

  2012cites this paper
• Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes.

  2012cites this paper
• P-Glycoprotein, Multidrug-Resistance Associated Protein 2, Cyp3a, and Carboxylesterase Affect the Oral Availability and Metabolism of Vinorelbine

  2012cites this paper
• Activity of the aurora kinase B inhibitor AZD1152 in acute myeloid leukaemia

  2012cites this paper
• Three decades of P-gp inhibitors: skimming through several generations and scaffolds.

  2012cites this paper
• Improving cancer chemotherapy with modulators of ABC drug transporters.

  2011cites this paper
• In vitro and In vivo Relevance of the P-glycoprotein Probe Substrates in Drug Discovery and Development: Focus on Rhodamine 123, Digoxin and Talinolol

  2011cites this paper